Finch Therapeutics Group (FNCH)
(Delayed Data from OTC)
$11.50 USD
+0.24 (2.13%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Finch Therapeutics Group, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 19 | 8 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 1 | 19 | 8 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 84 | 116 | 79 | 47 | 0 |
Income After Depreciation & Amortization | -84 | -116 | -60 | -39 | 0 |
Non-Operating Income | 6 | 1 | 2 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -78 | -115 | -58 | -39 | NA |
Income Taxes | -3 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -75 | -115 | -58 | -39 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -75 | -115 | -58 | -39 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -82 | -110 | -58 | -39 | 0 |
Depreciation & Amortization (Cash Flow) | 2 | 6 | 2 | 1 | NA |
Income After Depreciation & Amortization | -84 | -116 | -60 | -39 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.61 | 1.59 | 1.31 | NA | NA |
Diluted EPS Before Non-Recurring Items | -46.59 | -59.16 | -44.44 | NA | NA |
Diluted Net EPS (GAAP) | -46.59 | -72.07 | -44.44 | NA | NA |
Fiscal Year end for Finch Therapeutics Group, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.11 | 5.20 | 2.83 | 3.78 | 9.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.11 | -5.20 | -2.83 | -3.78 | -9.88 |
Non-Operating Income | 1.28 | 1.04 | 1.04 | 0.97 | 2.51 |
Interest Expense | 0.00 | -0.28 | 1.24 | -0.39 | -0.42 |
Pretax Income | -4.83 | -3.88 | -1.45 | -2.42 | -6.95 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.83 | -3.88 | -1.45 | -2.42 | -6.95 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.83 | -3.88 | -1.45 | -2.42 | -6.95 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 |
Diluted EPS Before Non-Recurring Items | -3.01 | -2.41 | -1.89 | -1.51 | -4.33 |
Diluted Net EPS (GAAP) | -3.01 | -2.41 | -0.81 | -1.51 | -4.33 |